Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP

Key Points

• Braidwell LP cut its Kiniksa Pharmaceuticals stake by 32.5% in the second quarter, selling 88,700 shares and retaining 183,822 shares valued at approximately $11.8 million. Institutional investors and hedge funds collectively own 53.95% of KNSA.
• Analyst sentiment remains positive, with eight Buy ratings and two Holds contributing to a consensus “Moderate Buy” rating and an average price target of $87.38. Several firms recently raised their targets to between $98 and $100.
• KNSA opened at $79.89, near its 52-week high of $82.94, after reporting quarterly revenue of $243.6 million—above the $226.5 million analyst estimate—while earnings of $0.30 per share matched expectations.

Braidwell LP lessened its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 32.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 183,822 shares of the company's stock after selling 88,700 shares during the quarter. Braidwell LP owned 0.24% of Kiniksa Pharmaceuticals International worth $11,755,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of KNSA. Nykredit A S acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth about $34,000. Headlands Technologies LLC acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $1,161,000. Handelsbanken Fonder AB acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $1,343,000. Financial Enhancement Group LLC purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $2,007,000. Finally, Bank of America Corp DE raised its position in Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company's stock worth $35,436,000 after buying an additional 506,576 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director G Bradley Cole sold 3,673 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 51.98% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an "overweight" rating in a report on Monday, July 13th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, August 13th. Finally, Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Moderate Buy" and an average price target of $87.38.

Kiniksa Pharmaceuticals International Stock Up 0.8%

KNSA stock opened at $79.89 on Thursday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $34.00 and a 52-week high of $82.94. The firm has a market cap of $6.23 billion, a P/E ratio of 82.36 and a beta of 0.09. The company's 50-day simple moving average is $71.13 and its 200-day simple moving average is $56.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The firm had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source